Form DEFR14A - Revised definitive proxy soliciting materials
13 Octobre 2023 - 11:00PM
Edgar (US Regulatory)
trueDEFR14A0000943819ResMed Inc.Add Inline XBRL tagging to pay vs performance section00009438192022-07-012023-06-30iso4217:USD00009438192021-07-012022-06-3000009438192020-07-012021-06-300000943819rmd:EquityAwardsReportedValueMemberecd:PeoMember2020-07-012021-06-300000943819rmd:EquityAwardsReportedValueMemberecd:PeoMember2021-07-012022-06-300000943819rmd:EquityAwardsReportedValueMemberecd:PeoMember2022-07-012023-06-300000943819ecd:PeoMemberrmd:EquityAwardsGrantedDuringTheYearUnvestedMember2020-07-012021-06-300000943819ecd:PeoMemberrmd:EquityAwardsGrantedDuringTheYearUnvestedMember2021-07-012022-06-300000943819ecd:PeoMemberrmd:EquityAwardsGrantedDuringTheYearUnvestedMember2022-07-012023-06-300000943819ecd:PeoMemberrmd:EquityAwardsGrantedInPriorYearsUnvestedMember2020-07-012021-06-300000943819ecd:PeoMemberrmd:EquityAwardsGrantedInPriorYearsUnvestedMember2021-07-012022-06-300000943819ecd:PeoMemberrmd:EquityAwardsGrantedInPriorYearsUnvestedMember2022-07-012023-06-300000943819ecd:PeoMemberrmd:EquityAwardsGrantedDuringTheYearVestedMember2020-07-012021-06-300000943819ecd:PeoMemberrmd:EquityAwardsGrantedDuringTheYearVestedMember2021-07-012022-06-300000943819ecd:PeoMemberrmd:EquityAwardsGrantedDuringTheYearVestedMember2022-07-012023-06-300000943819rmd:EquityAwardsGrantedInPriorYearsVestedMemberecd:PeoMember2020-07-012021-06-300000943819rmd:EquityAwardsGrantedInPriorYearsVestedMemberecd:PeoMember2021-07-012022-06-300000943819rmd:EquityAwardsGrantedInPriorYearsVestedMemberecd:PeoMember2022-07-012023-06-300000943819ecd:PeoMemberrmd:EquityAwardsThatFailedToMeetVestingConditionsMember2020-07-012021-06-300000943819ecd:PeoMemberrmd:EquityAwardsThatFailedToMeetVestingConditionsMember2021-07-012022-06-300000943819ecd:PeoMemberrmd:EquityAwardsThatFailedToMeetVestingConditionsMember2022-07-012023-06-300000943819ecd:PeoMember2020-07-012021-06-300000943819ecd:PeoMember2021-07-012022-06-300000943819ecd:PeoMember2022-07-012023-06-300000943819rmd:EquityAwardsReportedValueMemberecd:NonPeoNeoMember2020-07-012021-06-300000943819rmd:EquityAwardsReportedValueMemberecd:NonPeoNeoMember2021-07-012022-06-300000943819rmd:EquityAwardsReportedValueMemberecd:NonPeoNeoMember2022-07-012023-06-300000943819ecd:NonPeoNeoMemberrmd:EquityAwardsGrantedDuringTheYearUnvestedMember2020-07-012021-06-300000943819ecd:NonPeoNeoMemberrmd:EquityAwardsGrantedDuringTheYearUnvestedMember2021-07-012022-06-300000943819ecd:NonPeoNeoMemberrmd:EquityAwardsGrantedDuringTheYearUnvestedMember2022-07-012023-06-300000943819ecd:NonPeoNeoMemberrmd:EquityAwardsGrantedInPriorYearsUnvestedMember2020-07-012021-06-300000943819ecd:NonPeoNeoMemberrmd:EquityAwardsGrantedInPriorYearsUnvestedMember2021-07-012022-06-300000943819ecd:NonPeoNeoMemberrmd:EquityAwardsGrantedInPriorYearsUnvestedMember2022-07-012023-06-300000943819rmd:EquityAwardsGrantedDuringTheYearVestedMemberecd:NonPeoNeoMember2020-07-012021-06-300000943819rmd:EquityAwardsGrantedDuringTheYearVestedMemberecd:NonPeoNeoMember2021-07-012022-06-300000943819rmd:EquityAwardsGrantedDuringTheYearVestedMemberecd:NonPeoNeoMember2022-07-012023-06-300000943819rmd:EquityAwardsGrantedInPriorYearsVestedMemberecd:NonPeoNeoMember2020-07-012021-06-300000943819rmd:EquityAwardsGrantedInPriorYearsVestedMemberecd:NonPeoNeoMember2021-07-012022-06-300000943819rmd:EquityAwardsGrantedInPriorYearsVestedMemberecd:NonPeoNeoMember2022-07-012023-06-300000943819ecd:NonPeoNeoMemberrmd:EquityAwardsThatFailedToMeetVestingConditionsMember2020-07-012021-06-300000943819ecd:NonPeoNeoMemberrmd:EquityAwardsThatFailedToMeetVestingConditionsMember2021-07-012022-06-300000943819ecd:NonPeoNeoMemberrmd:EquityAwardsThatFailedToMeetVestingConditionsMember2022-07-012023-06-300000943819ecd:NonPeoNeoMember2020-07-012021-06-300000943819ecd:NonPeoNeoMember2021-07-012022-06-300000943819ecd:NonPeoNeoMember2022-07-012023-06-30000094381912022-07-012023-06-30000094381922022-07-012023-06-30000094381932022-07-012023-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Amendment No. 1)
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
| | | | | | | | | | | | | | |
o | Preliminary Proxy Statement | | o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
o | Definitive Proxy Statement | | |
x | Definitive Additional Materials | | | |
o | Soliciting Material Pursuant to § 240.14A-12 | | | |
| | |
|
(Name of Registrant as Specified in its Charter) |
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
| | | | | |
Payment of Filing Fee (Check all boxes that apply): |
x | No fee required. |
| |
o | Fee paid previously with preliminary materials. |
| |
o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| |
EXPLANATORY NOTE
This amendment to the proxy statement of ResMed Inc. filed on October 5, 2023 (the "Proxy Statement") amends the Pay vs Performance section of the Proxy Statement solely for the purpose of including the required Inline XBRL tagging, as the Proxy Statement inadvertently did not have complete XBRL tagging. There are no other changes to the Pay vs Performance section, or or any other portion of, the Proxy Statement.
Pay versus Performance
In accordance with Item 402(v) of Regulation S-K, we are providing the following information regarding the relationship between “compensation actually paid” to our CEO, or Principal Executive Officer (PEO), and our other named executive officers (Non-PEO NEOs) and certain financial performance measures for the fiscal years ended on June 30, 2023, June 30, 2022, and June 30, 2021. For further information on ResMed's pay-for-performance philosophy and how executive compensation aligns with Company performance, refer to the above section entitled “Compensation Discussion & Analysis” (“CD&A”).
| | | | | | | | | | | | | | | | | | | | | | | | | | |
Fiscal Year
| Summary Compensation Table Total for PEO (1) | Compensation Actually Paid to PEO (2) | Average Summary Compensation Table Total for non-PEO NEOs (3) | Average Compensation Actually Paid to non-PEO NEOs (4) | Value of Initial Fixed $100 Investment Based On: | Net Income ($M)
| Adjusted Net Sales ($M) (6) |
RMD Total Shareholder Return
| Dow Jones US Med. Equipment Total Shareholder Return (5) |
2023 | $13,868,641 | $16,867,038 | $4,147,542 | $4,909,275 | $113.80 | $129.79 | $897.6 | $4,163.2 |
2022 | $11,659,215 | $4,374,620 | $3,625,326 | -$55,486 | $109.18 | $114.04 | $779.4 | $3,616.1 |
2021 | $10,389,326 | $32,799,199 | $4,165,235 | $12,203,786 | $128.40 | $135.10 | $474.5 | $3,174.3 |
1.ResMed had one Principal Executive Officer or “PEO”, Mr. Michael Farrell, during fiscal years 2023, 2022, and 2021.
2.SEC rules require certain adjustments be made to the “Total” column as reported in the Summary Compensation Table to determine “Compensation Actually Paid” as reported in the Pay versus Performance Table (“PVP Table”). “Compensation Actually Paid” does not necessarily represent cash and/or equity value transferred to the applicable NEO without restriction, but rather is a value calculated under applicable SEC rules. The equity values are calculated in accordance with ASC Topic 718, with dividends being reflected in the fair value of the award. Valuation assumptions used to calculate fair values used a consistent process as done on the date of grant and were not materially different from those disclosed at the time of grant. The closing stock price of our common stock on June 30, 2020, June 30, 2021, June 30, 2022, and June 30, 2023, was $192.00, $246.52, $209.63 and $218.50. The following tables detail these adjustments for the PEO:
| | | | | | | | | | | |
PEO | | | |
Prior FYE | 6/30/2020 | 6/30/2021 | 6/30/2022 |
Current FYE | 6/30/2021 | 6/30/2022 | 6/30/2023 |
Fiscal Year | 2021 | 2022 | 2023 |
Summary Compensation Table Total | $ | 10,389,326 | $ | 11,659,215 | $ | 13,868,641 |
- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year | $ | (7,700,011) | $ | (9,000,005) | $ | (10,999,975) |
+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year | $ | 9,967,171 | $ | 6,170,624 | $ | 10,216,009 |
+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years | $ | 15,351,855 | $ | (5,637,001) | $ | (1,315,735) |
+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year | $ | — | $ | — | $ | — |
+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | $ | 4,790,858 | $ | 1,181,787 | $ | 5,098,098 |
- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year | $ | — | $ | — | $ | — |
Total Adjustments | $ | 22,409,873 | $ | (7,284,595) | $ | 2,998,397 |
Compensation Actually Paid | $ | 32,799,199 | $ | 4,374,620 | $ | 16,867,038 |
3. Non-PEO NEOs included for the fiscal years 2023, 2022 and 2021 are reflected in the table below:
| | | | | |
Fiscal Year | Non-PEO NEOs |
2023 | Lucile Blaise, Rob Douglas, Bobby Ghoshal, Brett Sandercock |
2022 | Rob Douglas, Bobby Ghoshal, Jim Hollingshead, David Pendarvis, Brett Sandercock |
2021 | Rob Douglas, Jim Hollingshead, Brett Sandercock, Raj Sodhi |
4. As discussed in footnote 2, SEC rules require certain adjustments to be made to determine “compensation actually paid” as reported in the Pay versus Performance table above. The following table details these adjustments to the Average Summary Compensation Table Total for Non-PEO NEOs.
| | | | | | | | | | | |
Average of Non-PEO NEOs | | | |
Prior FYE | 6/30/2020 | 6/30/2021 | 6/30/2022 |
Current FYE | 6/30/2021 | 6/30/2022 | 6/30/2023 |
Fiscal Year | 2021 | 2022 | 2023 |
Summary Compensation Table Total | $ | 4,165,235 | $ | 3,625,326 | $ | 4,147,542 |
- Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year | $ | (2,775,010) | $ | (2,500,046) | $ | (2,821,097) |
+ Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year | $ | 3,708,490 | $ | 1,328,777 | $ | 2,643,811 |
+ Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years | $ | 5,495,623 | $ | (1,432,485) | $ | (346,310) |
+ Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year | $ | — | $ | — | $ | — |
+ Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | $ | 1,609,448 | $ | 390,289 | $ | 1,285,329 |
- Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year | $ | — | $ | (1,467,347) | $ | — |
Total Adjustments | $ | 8,038,551 | $ | (3,680,812) | $ | 761,733 |
Compensation Actually Paid | $ | 12,203,786 | $ | (55,486) | $ | 4,909,275 |
5. The Dow Jones U.S. Medical Equipment index is one of the two index peer groups disclosed in our 10-K and we selected this index as our peer group for purposes of this disclosure, which is comprised of 61 companies from the Dow Jones U.S. Broad Stock Market Index that are classified in the DJICS Medical Equipment subsection. The Company’s fiscal 2023 performance-based long-term incentive program did not use this relative TSR as a financial performance measure. See the CD&A section titled “Long Term Incentives” in this Proxy Statement for additional information.
6. Adjusted Net Sales represents the most important financial performance measure (that is not otherwise required to be disclosed in the table) used by the Company to link compensation actually paid to our NEOs, including our CEO, for the most recently completed fiscal year to the Company’s performance. Adjusted Net Sales is a non-GAAP measure and is calculated as net sales on a GAAP basis excluding the impact of revenue from acquisitions completed after the establishment of the internal financial plan, as applicable, and foreign currency fluctuations. For a reconciliation of Adjusted Net Sales to the most directly comparable GAAP financial measure and insight into how Adjusted Net Sales is considered by management, please see Page 56 under "Elements of Compensation - Annual Cash Incentive Plan - Incentive Plan Adjustments."
Analysis of the Information Presented in the Pay versus Performance Table
In this section, we provide a graphic analysis showing, for the past three years, the relationship between our PEO’s and the Average of the Non-PEO NEOs’ “Compensation Actually Paid” and (i) the Company’s Adjusted Net Sales, (ii) the Company’s Net Income and (iii) the Company’s TSR, and additionally, the TSR of the Dow Jones U.S. Medical Equipment Index, one of the disclosed peer groups from our 10-K filing. As described in more detail in the CD&A, our executive compensation program reflects a pay-for-performance philosophy that emphasizes long-term equity awards intended to align our executives’ interests with stockholders’ long-term interests. Thus, the value of these awards and, therefore, a large portion of the compensation actual paid to our NEOs is inherently correlated to the Company’s stock price over time. Please refer to the section entitled CD&A above for more information about our executive compensation program.
Tabular list of Financial Performance Measures
The Company’s Compensation Committee believes in a holistic evaluation of our NEOs, and the Company’s performance measures throughout our annual focal and long-term incentive compensation programs to align executive pay with Company performance. As required by SEC rules, the performance measures are identified as the most important used to link the “Compensation Actually Paid” to our NEOs for fiscal 2023 compensation to the Company’s performance are listed in the table below, each of which is described in more detail in the section entitled “CD&A-Performance Metrics and Targets.”
| | |
Financial Performance Measures |
Adjusted Net Sales |
Net Operating Profit |
Total Shareholder Return (TSR) |
v3.23.3
X |
- DefinitionDescription of changes contained within amended document.
+ References
+ Details
Name: |
dei_AmendmentDescription |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.3
Pay vs Performance Disclosure - USD ($)
|
12 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2021 |
Pay vs Performance Disclosure [Table] |
|
|
|
Pay vs Performance [Table Text Block] |
| | | | | | | | | | | | | | | | | | | | | | | | | | | Fiscal Year
| Summary Compensation Table Total for PEO (1) | Compensation Actually Paid to PEO (2) | Average Summary Compensation Table Total for non-PEO NEOs (3) | Average Compensation Actually Paid to non-PEO NEOs (4) | Value of Initial Fixed $100 Investment Based On: | Net Income ($M)
| Adjusted Net Sales ($M) (6) | RMD Total Shareholder Return
| Dow Jones US Med. Equipment Total Shareholder Return (5) | 2023 | $13,868,641 | $16,867,038 | $4,147,542 | $4,909,275 | $113.80 | $129.79 | $897.6 | $4,163.2 | 2022 | $11,659,215 | $4,374,620 | $3,625,326 | -$55,486 | $109.18 | $114.04 | $779.4 | $3,616.1 | 2021 | $10,389,326 | $32,799,199 | $4,165,235 | $12,203,786 | $128.40 | $135.10 | $474.5 | $3,174.3 |
|
|
|
Company Selected Measure Name |
Adjusted Net Sales
|
|
|
Named Executive Officers, Footnote [Text Block] |
ResMed had one Principal Executive Officer or “PEO”, Mr. Michael Farrell, during fiscal years 2023, 2022, and 2021.Non-PEO NEOs included for the fiscal years 2023, 2022 and 2021 are reflected in the table below: | | | | | | Fiscal Year | Non-PEO NEOs | 2023 | Lucile Blaise, Rob Douglas, Bobby Ghoshal, Brett Sandercock | 2022 | Rob Douglas, Bobby Ghoshal, Jim Hollingshead, David Pendarvis, Brett Sandercock | 2021 | Rob Douglas, Jim Hollingshead, Brett Sandercock, Raj Sodhi |
|
|
|
Peer Group Issuers, Footnote [Text Block] |
. The Dow Jones U.S. Medical Equipment index is one of the two index peer groups disclosed in our 10-K and we selected this index as our peer group for purposes of this disclosure, which is comprised of 61 companies from the Dow Jones U.S. Broad Stock Market Index that are classified in the DJICS Medical Equipment subsection. The Company’s fiscal 2023 performance-based long-term incentive program did not use this relative TSR as a financial performance measure. See the CD&A section titled “Long Term Incentives” in this Proxy Statement for additional information.
|
|
|
PEO Total Compensation Amount |
$ 13,868,641
|
$ 11,659,215
|
$ 10,389,326
|
PEO Actually Paid Compensation Amount |
$ 16,867,038
|
4,374,620
|
32,799,199
|
Adjustment To PEO Compensation, Footnote [Text Block] |
SEC rules require certain adjustments be made to the “Total” column as reported in the Summary Compensation Table to determine “Compensation Actually Paid” as reported in the Pay versus Performance Table (“PVP Table”). “Compensation Actually Paid” does not necessarily represent cash and/or equity value transferred to the applicable NEO without restriction, but rather is a value calculated under applicable SEC rules. The equity values are calculated in accordance with ASC Topic 718, with dividends being reflected in the fair value of the award. Valuation assumptions used to calculate fair values used a consistent process as done on the date of grant and were not materially different from those disclosed at the time of grant. The closing stock price of our common stock on June 30, 2020, June 30, 2021, June 30, 2022, and June 30, 2023, was $192.00, $246.52, $209.63 and $218.50. The following tables detail these adjustments for the PEO: | | | | | | | | | | | | PEO | | | | Prior FYE | 6/30/2020 | 6/30/2021 | 6/30/2022 | Current FYE | 6/30/2021 | 6/30/2022 | 6/30/2023 | Fiscal Year | 2021 | 2022 | 2023 | Summary Compensation Table Total | $ | 10,389,326 | $ | 11,659,215 | $ | 13,868,641 | - Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year | $ | (7,700,011) | $ | (9,000,005) | $ | (10,999,975) | + Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year | $ | 9,967,171 | $ | 6,170,624 | $ | 10,216,009 | + Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years | $ | 15,351,855 | $ | (5,637,001) | $ | (1,315,735) | + Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year | $ | — | $ | — | $ | — | + Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | $ | 4,790,858 | $ | 1,181,787 | $ | 5,098,098 | - Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year | $ | — | $ | — | $ | — | Total Adjustments | $ | 22,409,873 | $ | (7,284,595) | $ | 2,998,397 | Compensation Actually Paid | $ | 32,799,199 | $ | 4,374,620 | $ | 16,867,038 |
|
|
|
Non-PEO NEO Average Total Compensation Amount |
$ 4,147,542
|
3,625,326
|
4,165,235
|
Non-PEO NEO Average Compensation Actually Paid Amount |
$ 4,909,275
|
(55,486)
|
12,203,786
|
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] |
As discussed in footnote 2, SEC rules require certain adjustments to be made to determine “compensation actually paid” as reported in the Pay versus Performance table above. The following table details these adjustments to the Average Summary Compensation Table Total for Non-PEO NEOs. | | | | | | | | | | | | Average of Non-PEO NEOs | | | | Prior FYE | 6/30/2020 | 6/30/2021 | 6/30/2022 | Current FYE | 6/30/2021 | 6/30/2022 | 6/30/2023 | Fiscal Year | 2021 | 2022 | 2023 | Summary Compensation Table Total | $ | 4,165,235 | $ | 3,625,326 | $ | 4,147,542 | - Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year | $ | (2,775,010) | $ | (2,500,046) | $ | (2,821,097) | + Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year | $ | 3,708,490 | $ | 1,328,777 | $ | 2,643,811 | + Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years | $ | 5,495,623 | $ | (1,432,485) | $ | (346,310) | + Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year | $ | — | $ | — | $ | — | + Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year | $ | 1,609,448 | $ | 390,289 | $ | 1,285,329 | - Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year | $ | — | $ | (1,467,347) | $ | — | Total Adjustments | $ | 8,038,551 | $ | (3,680,812) | $ | 761,733 | Compensation Actually Paid | $ | 12,203,786 | $ | (55,486) | $ | 4,909,275 |
|
|
|
Compensation Actually Paid vs. Total Shareholder Return [Text Block] |
|
|
|
Compensation Actually Paid vs. Net Income [Text Block] |
|
|
|
Compensation Actually Paid vs. Company Selected Measure [Text Block] |
|
|
|
Total Shareholder Return Vs Peer Group [Text Block] |
|
|
|
Tabular List [Table Text Block] |
| | | Financial Performance Measures | Adjusted Net Sales | Net Operating Profit | Total Shareholder Return (TSR) |
|
|
|
Total Shareholder Return Amount |
$ 113.80
|
109.18
|
128.40
|
Peer Group Total Shareholder Return Amount |
129.79
|
114.04
|
135.10
|
Net Income (Loss) |
$ 897,600,000
|
$ 779,400,000
|
$ 474,500,000
|
Company Selected Measure Amount |
4,163,200,000
|
3,616,100,000
|
3,174,300,000
|
PEO Name |
Mr. Michael Farrell
|
|
|
Measure [Axis]: 1 |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Measure Name |
Adjusted Net Sales
|
|
|
Non-GAAP Measure Description [Text Block] |
. Adjusted Net Sales represents the most important financial performance measure (that is not otherwise required to be disclosed in the table) used by the Company to link compensation actually paid to our NEOs, including our CEO, for the most recently completed fiscal year to the Company’s performance. Adjusted Net Sales is a non-GAAP measure and is calculated as net sales on a GAAP basis excluding the impact of revenue from acquisitions completed after the establishment of the internal financial plan, as applicable, and foreign currency fluctuations. For a reconciliation of Adjusted Net Sales to the most directly comparable GAAP financial measure and insight into how Adjusted Net Sales is considered by management, please see Page 56 under "Elements of Compensation - Annual Cash Incentive Plan - Incentive Plan Adjustments."
|
|
|
Measure [Axis]: 2 |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Measure Name |
Net Operating Profit
|
|
|
Measure [Axis]: 3 |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Measure Name |
Total Shareholder Return (TSR)
|
|
|
PEO [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
$ 2,998,397
|
$ (7,284,595)
|
$ 22,409,873
|
PEO [Member] | Equity Awards Reported Value [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
(10,999,975)
|
(9,000,005)
|
(7,700,011)
|
PEO [Member] | Equity Awards Granted During the Year, Unvested [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
10,216,009
|
6,170,624
|
9,967,171
|
PEO [Member] | Equity Awards Granted in Prior Years, Unvested [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
(1,315,735)
|
(5,637,001)
|
15,351,855
|
PEO [Member] | Equity Awards Granted During the Year, Vested [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
0
|
0
|
0
|
PEO [Member] | Equity Awards Granted in Prior Years, Vested [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
5,098,098
|
1,181,787
|
4,790,858
|
PEO [Member] | Equity Awards that Failed to Meet Vesting Conditions [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
0
|
0
|
0
|
Non-PEO NEO [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
761,733
|
(3,680,812)
|
8,038,551
|
Non-PEO NEO [Member] | Equity Awards Reported Value [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
(2,821,097)
|
(2,500,046)
|
(2,775,010)
|
Non-PEO NEO [Member] | Equity Awards Granted During the Year, Unvested [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
2,643,811
|
1,328,777
|
3,708,490
|
Non-PEO NEO [Member] | Equity Awards Granted in Prior Years, Unvested [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
(346,310)
|
(1,432,485)
|
5,495,623
|
Non-PEO NEO [Member] | Equity Awards Granted During the Year, Vested [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
0
|
0
|
0
|
Non-PEO NEO [Member] | Equity Awards Granted in Prior Years, Vested [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
1,285,329
|
390,289
|
1,609,448
|
Non-PEO NEO [Member] | Equity Awards that Failed to Meet Vesting Conditions [Member] |
|
|
|
Pay vs Performance Disclosure [Table] |
|
|
|
Adjustment to Compensation Amount |
$ 0
|
$ (1,467,347)
|
$ 0
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3
+ Details
Name: |
ecd_AdjToCompAmt |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3
+ Details
Name: |
ecd_AdjToNonPeoNeoCompFnTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3
+ Details
Name: |
ecd_AdjToPeoCompFnTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi
+ Details
Name: |
ecd_CoSelectedMeasureAmt |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:decimalItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi
+ Details
Name: |
ecd_CoSelectedMeasureName |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii
+ Details
Name: |
ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii
+ Details
Name: |
ecd_CompActuallyPaidVsNetIncomeTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i
+ Details
Name: |
ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi
+ Details
Name: |
ecd_MeasureName |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3
+ Details
Name: |
ecd_NamedExecutiveOfficersFnTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi
+ Details
Name: |
ecd_NonGaapMeasureDescriptionTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii
+ Details
Name: |
ecd_NonPeoNeoAvgCompActuallyPaidAmt |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii
+ Details
Name: |
ecd_NonPeoNeoAvgTotalCompAmt |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv
+ Details
Name: |
ecd_PeerGroupIssuersFnTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv
+ Details
Name: |
ecd_PeerGroupTotalShareholderRtnAmt |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii
+ Details
Name: |
ecd_PeoActuallyPaidCompAmt |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3
+ Details
Name: |
ecd_PeoName |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii
+ Details
Name: |
ecd_PeoTotalCompAmt |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1
+ Details
Name: |
ecd_PvpTable |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1
+ Details
Name: |
ecd_PvpTableTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6
+ Details
Name: |
ecd_TabularListTableTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv
+ Details
Name: |
ecd_TotalShareholderRtnAmt |
Namespace Prefix: |
ecd_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv
+ Details
Name: |
ecd_TotalShareholderRtnVsPeerGroupTextBlock |
Namespace Prefix: |
ecd_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227
Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580
Reference 25: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
ecd_MeasureAxis=1 |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_MeasureAxis=2 |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_MeasureAxis=3 |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_ExecutiveCategoryAxis=ecd_PeoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_AdjToCompAxis=rmd_EquityAwardsReportedValueMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_AdjToCompAxis=rmd_EquityAwardsGrantedDuringTheYearUnvestedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_AdjToCompAxis=rmd_EquityAwardsGrantedInPriorYearsUnvestedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_AdjToCompAxis=rmd_EquityAwardsGrantedDuringTheYearVestedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_AdjToCompAxis=rmd_EquityAwardsGrantedInPriorYearsVestedMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_AdjToCompAxis=rmd_EquityAwardsThatFailedToMeetVestingConditionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
ResMed (NYSE:RMD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
ResMed (NYSE:RMD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024